Although ICIs targeting PD-1 and CTLA-4 have proven to be effective in treating locally advanced or metastatic carcinoma, a significant portion of patients fail to respond to the treatment or experience early recurrence 40. This evidence concerns the gene CTLA4 and metastatic carcinoma.